|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||84.61 - 84.61|
|52-week range||72.98 - 93.58|
|Beta (5Y monthly)||0.47|
|PE ratio (TTM)||27.65|
|Forward dividend & yield||3.49 (4.22%)|
|Ex-dividend date||09 Mar 2023|
|1y target est||N/A|
Novartis (NVS) reports mixed fourth-quarter results, with key brands maintaining momentum but Cosentyx sales declining and generic competition remaining a drag.
NVS earnings call for the period ending December 31, 2022.
Novartis on Wednesday predicted that core operating income would grow in a "mid single digit" percentage range in 2023 following stagnation last year, as the Swiss drugmaker prepares to spin off its Sandoz generics business. Full-year core operating income was broadly flat at $16.7 billion, it said in a statement, coming in slightly below market expectations of $16.8 billion. Adjusted for overall negative currency effects, group sales in 2022 advanced 4% to $50.5 billion as gains from heart failure drug Entresto and multiple sclerosis (MS) drug Kesimpta were partly offset by competition from cheap generic copies of established MS drug Gilenya.